Charles River International Laboratories, Inc. (CRL) recently launched Endosafe Trillium rCR cartridges, which combine its hallmark Endosafe cartridge technology with recombinant cascade reagent (rCR). The latest launch expanded the company’s robust bacterial endotoxin testing (BET) portfolio with a new animal-free testing solution.The recent development will bolster the Charles River Microbial Solutions business.More on the LaunchThe latest launch, which expands Charles River's existing Trillium rCR vial p ...

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2023 financial results and provide 2024 guidance on Wednesday, February 14th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, February 14th, at 8:30 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.cri ...

Charles River Laboratories International, Inc. (NYSE:CRL) Q3 2023 Earnings Conference Call November 8, 2023 8:30 AM ET Company Participants Todd Spencer - Vice President, Investor Relations Jim Foster - Chairman, President & Chief Executive Officer Flavia Pease - Executive Vice President & Chief Financial Officer Conference Call Participants Eric Coldwell - Baird Elizabeth Anderson - Evercore Derik De Bruin - Bank of America Casey Woodring - JPMorgan Patrick Donnelly - Citi Dave Windley - Jefferies Justin B ...

| --- | --- | --- | --- | |----------------------|--------|-------|--------------| | ($ in millions) | 3Q23 | 3Q22 | 2023 Outlook | | Free cash flow (FCF) | $139.5 | $60.4 | $340-$360 | | Capex | $65.9 | $72.4 | $330-$340 | | Depreciation | $44.6 | $39.1 | ~$180 | | Amortization (1) | $34.2 | $35.5 | $135-$140 | ─ Continue to take a disciplined approach to managing capital deployment and are committed to aligning capacity and capital investments with current demand trends | --- | --- | --- | |-------------- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jur ...

Flavia Pease - Executive Vice President and Chief Financial Officer Tejas Savant - Morgan Stanley Dave Windley - Jefferies I would now like to turn the conference over to our host, Todd Spencer, Vice President of Investor Relations. Please go ahead. During this call, we will primarily discuss non-GAAP financial measures, which we believe help investors gain a meaningful understanding of our core operating results and guidance. The non-GAAP financial measures are not meant to be considered superior to or a s ...

See ir.criver.com for reconciliations of GAAP to Non-GAAP results. | --- | --- | --- | --- | |----------------------------------------|--------|--------|-------| | ($ in millions) | 2Q23 | 2Q22 | YOY Δ | | Revenue, reported | $209.9 | $186.4 | 12.6% | | Unfavorable/(Favorable) impact of FX | | | 1.3% | | Revenue growth, organic | | | 13.9% | EVERY STEP OF THE WAY RMS Results – Research Models ▪ While growth rates cooled a bit in 2Q23, continuing to see stable demand and pricing for small research models in ...

▪ Believe early-stage research we conduct is instrumental to our biotech clients' achievement of important milestones that enable them to secure additional funding Concluding Remarks, cont. ─ Investing in technology partnerships to bring cutting-edge tools to our clients EVERY STEP OF THE WAY ─ Delivered strong organic revenue growth, widely outperforming prior expectations ▪ Narrowed 2023 financial guidance to reflect strong 1Q23 performance ─ Anticipated gating of NHP supply impact, which will principally ...

Company Participants Conference Call Participants Operator I would now like to turn the conference over to our host, Todd Spencer, Vice President of Investor Relations. Please go ahead. Good morning, and welcome to Charles River Laboratories first quarter 2023 earnings conference call and webcast. This morning, I am joined by Jim Foster, Chairman, President and Chief Executive Officer; and Flavia Pease, Executive Vice President and Chief Financial Officer. They will comment on our results for the first quar ...

Financial Data and Key Metrics Changes - The company reported record quarterly revenue of $1.1 billion in Q4 2022, marking a 21.5% increase on a reported basis [62] - For the full year 2022, revenue reached $3.98 billion, with a reported growth rate of 12.3% and an organic growth rate of 13.4% [63] - Earnings per share (EPS) for Q4 2022 were $2.98, a 19.7% increase from $2.49 in Q4 2021, while full-year EPS was $11.12, a 7.8% increase over the prior year [91] Business Line Data and Key Metrics Changes - The Discovery and Safety Assessment (DSA) segment saw a substantial 26.5% increase in organic revenue in Q4, with a full-year organic growth rate of 17.5% [92] - Manufacturing Solutions revenue was $212.1 million in Q4, with a 5.3% organic growth rate, consistent with the mid-single-digit outlook for 2022 [71] - Research Model Services (RMS) revenue increased by 10.8% on an organic basis in Q4, driven by strong growth in North America and China [96] Market Data and Key Metrics Changes - The company noted that the current NHP supply situation may restrict revenue growth and margin expansion in 2023, with an expected organic revenue growth guidance of 4.5% to 7.5% [86] - North America continued to generate strong revenue growth, while China experienced a double-digit increase despite a modest impact from COVID cases [69] Company Strategy and Development Direction - The company aims to position itself as the non-clinical drug development partner of choice, focusing on early-stage research and strategic outsourcing [64] - The integration of acquired companies and expansion of capabilities through partnerships and M&A are key strategies to enhance service offerings [95] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the underlying business trends remaining intact in 2023 despite macroeconomic pressures [64] - The company is actively working to resolve the NHP supply situation, which is critical for the pharmaceutical industry and patient needs [58][84] Other Important Information - The company has voluntarily suspended planned future shipments of Cambodian NHPs until new procedures are developed to ensure compliance [57] - The investigation into NHP imports from Cambodia is expected to impact study timelines and revenue growth [56][86] Q&A Session Summary Question: What are your customers doing in the biotech space regarding studies? - Management indicated that the NHP supply issue is an industry-wide concern, affecting all vendors and potentially delaying drug development [112] Question: How closely are FDA and Fish and Wildlife working together? - Management confirmed that Fish and Wildlife understands the critical nature of NHPs and is engaged in discussions to resolve the supply issue [115] Question: Can you provide details on supply expansion beyond Cambodia? - Management mentioned ongoing efforts to audit and expand supply sources, ensuring compliance and quality from alternative suppliers [120]